PGPooja Gupta

Pooja Gupta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pooja Gupta has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Double‐Blind Randomised Controlled Trial Comparing the Efficacy of Nifedipine and Diltiazem Ointments in the Treatment of Anal Fissure

    by Arun Kumar, Raghav Garg, Pooja Gupta, Piyush Ranjan

    Background: Anal fissure, a common anorectal disorder, usually presents with pain, bleeding, and itching during or after defecation. These fissures can be classified as acute, chronic, or acute on chronic, depending on the duration of symptoms (6 weeks or less for acute and more than 6 weeks for chronic). Traditional treatment involves medical interventions to reduce sphincter tone and improve blood flow. Topical calcium channel blockers (CCBs) have shown promising results in conservative management. This study aimed to compare the efficacy and safety of Nifedipine versus Diltiazem ointments in treating anal fissures through a double‐blind, randomized controlled trial conducted at a tertiary care centre. Methods: From August 2022 to November 2023, 110 patients with acute, chronic, or acute‐on‐chronic anal fissures were randomized into two groups, receiving 1 g of either 0.3% Nifedipine and 2% lidocaine or 2% Diltiazem and 2% lidocaine ointments twice daily for 6 weeks. The primary outcome was assessed using the REALISE score, which measures pain, bleeding, and overall quality of life. Secondary outcomes included perianal irritation and adverse events. Results: Both treatments significantly improved the REALISE scores, with reductions from baseline to 6 weeks indicating effective symptom relief. Nifedipine reduced the score from 17.7 ± 3.9 to 5.3 ± 1.8 ( p = 0.0001), while Diltiazem reduced it from 16.3 ± 3.9 to 5.8 ± 2.3 ( p = 0.0001). Healing rates were comparable between groups (70.9% for Nifedipine and 67.3% for Diltiazem), and both treatments were well‐tolerated with minimal side effects. Conclusion: This study confirms that both Nifedipine and Diltiazem are effective first‐line treatments for anal fissures, offering viable short‐term non‐surgical options. Further research with longer follow‐up and multicentric studies is needed to evaluate long‐term outcomes and treatment combinations. Trial Registration: This study was registered in the Indian Clinical Trials Registry under the code: CTRI/2022/04/042081. Registered on April 22, 2022 (URL: https://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=66601&EncHid=71722.40664&modid=1&compid=19 )

  • Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients

    by Lavisha Goel, Pooja Gupta, Lalit Kumar, Thirumurthy Velpandian, Archana Singh, Kalpana Luthra, Yogendra Kumar Gupta


  • Open Access

    Prescription-based cost analysis of medicines for cardiovascular risk factors at Indian Council of Medical Research-Rational Use of Medicine Centre Hospitals of India

    by Preeta Kaur Chugh, Pooja Gupta, Himika Wasan, C. D. Tripathi, Sujith J. Chandy, Jaya Ranjalkar, Heber Rew Bright, Dinesh Kumar Badyal, Madhulika Peter Samuel, Ratinder Jhaj, et al.

    OBJECTIVES: India has taken several initiatives to provide health care to its population while keeping the related expenditure minimum. Since cardiovascular diseases are the most prevalent chronic conditions, in the present study, we aimed to analyze the difference in prices of medicines prescribed for three cardiovascular risk factors, based on (a) listed and not listed in the National List of Essential Medicines (NLEM) and (b) generic and branded drugs. MATERIALS AND METHODS: Outpatient prescriptions for diabetes mellitus, hypertension, and dyslipidemia were retrospectively analyzed from 12 tertiary centers. The prices of medicines prescribed were compared based on presence or absence in NLEM India-2015 and prescribing by generic versus brand name. The price was standardized and presented as average price per medicine per year for a given medicine. The results are presented in Indian rupee (INR) and as median (range). RESULTS: Of the 4,736 prescriptions collected, 843 contained oral antidiabetic, antihypertensive, and/or hypolipidemic medicines. The price per medicine per year for NLEM oral antidiabetics was INR 2849 (2593–3104) and for non-NLEM was INR 5343 (2964–14364). It was INR 806 (243–2132) for generic and INR 3809 (1968–14364) for branded antidiabetics. Antihypertensives and hypolipidemics followed the trend. The price of branded non-NLEM medicines was 5–22 times higher compared to generic NLEM which, for a population of 1.37 billion, would translate to a potential saving of 346.8 billion INR for statins. The variability was significant for sulfonylureas, angiotensin receptor blockers, beta-blockers, diuretics, and statins (P < 0.0001). CONCLUSION: The study highlights an urgent need for intervention to actualize the maximum benefit of government policies and minimize the out-of-pocket expenditure on medicines.


  • Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions

    by Archana Mishra, Rituparna Maiti, Prafull Mohan, Pooja Gupta

    Chimeric Antigen Receptor T‐cell (CAR‐T cell) therapy has emerged as a groundbreaking immunotherapeutic approach for treating various hematological malignancies. CAR‐T cells are engineered to express synthetic receptors that target specific antigens on cancer cells, leading to their eradication. While the therapy has shown remarkable efficacy, a significant challenge that has been observed in 30%–70% of patients showing recurrent disease is antigen loss or downregulation. We searched PubMed/MEDLINE, EMBASE, and Google scholar for articles on antigen loss/escape following Chimeric antigen receptor T‐cell therapy in malignancies. Antigen loss refers to the loss or reduction in the expression of the target antigen on cancer cells, rendering CAR‐T cells ineffective. This phenomenon poses a significant clinical concern, as it can lead to disease relapse and limited treatment options. This review explores the mechanisms underlying antigen loss following CAR‐T cell therapy, its implications on treatment outcomes, and potential strategies to overcome the problem.


  • Efficacy of the Implementation of Brain Herniation Codes at a Tertiary Medical Center (P1-7.005)

    by Eunice Lee, Lucy Gee, Malissa Pynes, Courtney Curran, Rebecca Hsu, Julian Gal, Jennifer Newman, Elizabeth Fletman, Pooja Gupta, Emma Yellin, et al.

    Objective: To reduce time to imaging and intervention for brain herniation codes through provider education. Background: Brain herniation is a life-threatening event that occurs when compensatory mechanisms are overcome by increasing intracranial pressure. At Thomas Jefferson University Hospital, we implemented a brain herniation code (BHC) alert in 2019 to help quickly mobilize resources and provide care for these patients. However, healthcare providers (HCP) were not aware of this system and thus underutilized. We aim to study the “time to intervention” and outcomes of BHC patients before and after teaching sessions with HCP. We hypothesize that the implementation of BHC with HCP education at TJUH will improve efficiency of clinical care as well as clinical outcomes. Design/Methods: We retrospectively evaluated “time to intervention” for BHC patient charts at TJUH between 2019 to 2021. We then provided educational sessions to HCP with a pre and post lecture evaluation. Statistical analysis was performed using Graphpad Prism v9. Pre and post survey results were compared using paired analysis corrected for multiple comparisons. Results: Preliminary data found six BHC patients before education sessions. The average time to CTH was 39.8 + 6.02 minutes and the average time to administering hyperosmolar therapy was 56.6 + 26.23 minutes. We found a statistically significant difference in pre and post test scores in non-neurology residents (p<0.001, n=20) and Neurology residents (p=0.046, n=12) following our teaching session. Non-neurology providers scored significantly better on 3 questions directed at recognizing impending herniation and 1 question about brain herniation protocol (p<0.05, n=20). Neurology residents scored significantly better on 1 question about protocol (p < 0.05, n = 12) post teaching session. Conclusions: We found focused teaching had improved general knowledge and comfort regarding BHC. We continue to collect post education data to see if there is an improvement in “time to intervention” and patient outcomes. Disclosure: Dr. Lee has nothing to disclose. Dr. Gee has nothing to disclose. Dr. Pynes has nothing to disclose. Dr. Curran has nothing to disclose. Dr. Hsu has nothing to disclose. Dr. Gal has nothing to disclose. Dr. Newman has nothing to disclose. Dr. Fletman has nothing to disclose. Dr. Gupta has nothing to disclose. Dr. Yellin has nothing to disclose. Dr. Buslov has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Navarathna has nothing to disclose. Dr. Vibbert has nothing to disclose. Dr. Shah has nothing to disclose.

  • Pharmacovigilance-Based Drug Repurposing

    by Pooja Gupta, Archana Mishra

  • Solid Lipid Nanoformulation of Berberine Attenuates Doxorubicin Triggered in vitro Inflammation in H9c2 Rat Cardiomyocytes

    by Pooja Gupta, Shalini Rawal, Priyanka Bhatnagar, Harlokesh Narayan Yadav, Amit Kumar Dinda

    Aim: To evaluate berberine solid lipid nanoparticles' efficacy against doxorubicin-induced cardiotoxicity. Background: Berberine (Ber) is cardioprotective, but its oral bioavailability is low and its effect in chemotherapy-induced cardiotoxicity has not been studied. Objective: Solid lipid nanoparticles (SLNs) of berberine chloride were prepared, characterized and evaluated in vitro against Doxorubicin induced cardiomyocyte injury. Methodology: Berberine loaded SLNs (Ber-SLNs) were synthesized using water-in-oil microemulsion technique with tripalmitin, Tween 80 and poloxamer 407. Ber-SLNs were evaluated for preventive effect against toxicity of Doxorubicin in H9c2 cells. The culture was pre-treated (24 h) with Ber (10 µM) and Ber-SLNs (1 and 10 µM) and exposed to 1 µM of Doxorubicin (Dox) was added for 3 h. The cell viability (LDH (Lactate dehydrogenase) assay and MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)), levels of Creatine kinase-MB (CK-MB), Nitrite, MDA (Malondialdehyde), ROS (Reactive oxygen species) generation and apoptotic DNA (Deoxyribonucleic acid) content were assessed. Results: Ber-SLNs had a mean particle size of 13.12±1.188 nm, zeta potential of -1.05 ± 0.08 mV, poly-dispersity index (PDI) of 0.317 ± 0.05 and entrapment efficiency of 50 ± 4.8%. Cell viability was 81  0.17% for Ber-SLNs (10 µM) and 73.22  0.83% for Ber (10 µM) treated cells in MTT assay. Percentage cytotoxicity calculated from LDH release was 58.91  0.54% after Dox, 40.3  1.3% with Ber (10 µM) and 40.7  1.3% with Ber-SLNs (1 µM) (p<0.001). Inflammation and oxidative stress markers were lower with Ber and Ber-SLNs. Attenuation of ROS generation and apoptosis of cardiomyocytes were noted on fluorescence microscopy. Conclusion: Ber loaded SLNs effectively prevented Doxorubicin-induced inflammation and oxidative stress in rat cardiomyocytes. The results demonstrate that microemulsion is a simple, cost-effective technique to prepare Ber-SLNs and may be considered as a drug delivery vehicle for berberine.


  • Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity

    by Pooja Gupta, Tavneet Kaur Makkar, Lavisha Goel, Monika Pahuja

    Chemotherapeutic agents may adversely affect the nervous system, including the neural precursor cells as well as the white matter. Although the mechanisms are not completely understood, several hypotheses connecting inflammation and oxidative stress with neurotoxicity are now emerging. The proposed mechanisms differ depending on the class of drug. For example, toxicity due to cisplatin occurs due to activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which alters hippocampal long-term potentiation. Free radical injury is also involved in the cisplatin-mediated neurotoxicity as dysregulation of nuclear factor erythroid 2-related factor 2 (Nrf2) has been seen which protects against the free radical injury by regulating glutathione S-transferases and hemeoxygenase-1 (HO-1). Thus, correcting the imbalance between NF-κB and Nrf2/HO-1 pathways may alleviate cisplatin-induced neurotoxicity. With newer agents like bortezomib, peripheral neuropathy occurs due to up-regulation of TNF-α and IL-6 in the sensory neurons. Superoxide dismutase dysregulation is also involved in bortezomib-induced neuropathy. This article reviews the available literature on inflammation and oxidative stress in neurotoxicity caused by various classes of chemotherapeutic agents. It covers the conventional medicines like platinum compounds, vinca alkaloids, and methotrexate, as well as the newer therapeutic agents like immunomodulators and immune checkpoint inhibitors. A better understanding of the pathophysiology will lead to further advancement in strategies for management of chemotherapy-induced neurotoxicity.